A randomized phase III trial exploring the prognostic value of extensive intraoperative peritoneal lavage in addition to standard treatment for resectable advanced gastric cancer: CCOG 1102 study

A randomized controlled trial has started in Japan to evaluate the efficacy of extensive intraoperative peritoneal lavage in the treatment of resectable advanced gastric cancer. Patients with T3 or deeper carcinoma of the stomach are intraoperatively randomized to either extensive intraoperative per...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Japanese journal of clinical oncology 2014-01, Vol.44 (1), p.101-103
Hauptverfasser:	Misawa, Kazunari, Mochizuki, Yoshinari, Ohashi, Norifumi, Matsui, Takanori, Nakayama, Hiroshi, Tsuboi, Kenji, Sakai, Mitsuru, Ito, Seiji, Morita, Satoshi, Kodera, Yasuhiro
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Antineoplastic Combined Chemotherapy Protocols - therapeutic use Carcinoma - mortality Carcinoma - pathology Carcinoma - surgery Carcinoma - therapy Chemotherapy, Cancer, Regional Perfusion Disease-Free Survival Female Gastrectomy Humans Japan - epidemiology Male Middle Aged Neoplasm Recurrence, Local - epidemiology Neoplasm Recurrence, Local - prevention & control Peritoneal Lavage Peritoneal Neoplasms - epidemiology Peritoneal Neoplasms - mortality Peritoneal Neoplasms - secondary Peritoneal Neoplasms - therapy Prognosis Stomach Neoplasms - mortality Stomach Neoplasms - pathology Stomach Neoplasms - surgery Stomach Neoplasms - therapy Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	A randomized controlled trial has started in Japan to evaluate the efficacy of extensive intraoperative peritoneal lavage in the treatment of resectable advanced gastric cancer. Patients with T3 or deeper carcinoma of the stomach are intraoperatively randomized to either extensive intraoperative peritoneal lavage + arm or extensive intraoperative peritoneal lavage- arm. A total of 300 patients will be accrued from 20 institutions. The primary endpoint is disease-free survival, and secondary end-points are overall survival, peritoneal recurrence-free survival and incidence of adverse events.
ISSN:	0368-2811 1465-3621
DOI:	10.1093/jjco/hyt157